Coefficient* | P value | |
SLAM-nolab versus | ||
Total Q-SLAQ | 0.709 | <0.001 |
Total Q-SLAQ with sicca | 0.690 | <0.001 |
Symptom Score | 0.680 | <0.001 |
Symptom Score with sicca | 0.674 | <0.001 |
Patient’s global disease activity | 0.683 | <0.001 |
SLAM versus | ||
Total Q-SLAQ | 0.528 | <0.001 |
Total Q-SLAQ with sicca | 0.505 | <0.001 |
Symptom Score | 0.496 | <0.001 |
Symptom Score with sicca | 0.488 | <0.001 |
Patient’s global disease activity | 0.529 | <0.001 |
SLEDAI-2K nolab versus | ||
Total Q-SLAQ | 0.303 | 0.001 |
Total Q-SLAQ with sicca | 0.274 | 0.004 |
Symptom Score | 0.301 | 0.001 |
Symptom Score with sicca | 0.292 | 0.002 |
Patient’s global disease activity | 0.361 | <0.001 |
SLEDAI-2K versus | ||
Total Q-SLAQ | −0.046 | 0.622 |
Total Q-SLAQ with sicca | −0.084 | 0.371 |
Symptom Score | −0.028 | 0.766 |
Symptom Score with sicca | −0.042 | 0.656 |
Patient’s global disease activity | 0.086 | 0.374 |
*Spearman correlation.
Q-SLAQ, Quick Systemic Lupus Activity Questionnaire; SLAM, SLE Activity Measure; SLAM-nolab, Systemic Lupus Activity Measure without laboratory parameters; SLEDAI-2K, SLE Disease Activity Index; SLEDAI-2K-nolab, SLE Disease Activity Index without laboratory parameters.